Please see 2nd reference. It lists a 2024 publicat
Post# of 148101
(Total Views: 434)
Posted On: 08/14/2024 6:39:31 PM
Please see 2nd reference. It lists a 2024 publication. Is this the cancer study Dr. Jay was trying to get published ?
2. Adams DL, Raghavakaimal A, Tang CM, et al. Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (leronlimab): a pooled analysis of three clinical trials in patients with mTNBC. J Clin Oncol. 2024;40(suppl 16). doi:10.1200/JCO.2022.40.16_suppl
2. Adams DL, Raghavakaimal A, Tang CM, et al. Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (leronlimab): a pooled analysis of three clinical trials in patients with mTNBC. J Clin Oncol. 2024;40(suppl 16). doi:10.1200/JCO.2022.40.16_suppl
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼